| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
CytoMed Therapeutics Limited$1.03
+0.05 (+5.1%)
F 16Pipeline Score Biotech · Clinical
Market Cap
13.37 M
EPS
-0.26
P/E Ratio
-
Value Trade
1.63 K
18.95 %
Week
10.78 %
1 Month
13.18 %
3 Month
-38.59 %
6 Month
-71.75 %
5 Year
-71.75 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
54.66 K
52 Week Range
0.68 - 3.68
% held by Insiders
47.02 %
% held by Institutions
0.14 %
Enterprise Value
12.36 M
Total Shares
11.73 M
Short %
0.73 %
Float Shares
4.65 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for CytoMed Therapeutics Limited
60Total events
3Upcoming
13Tier-1 (high impact)
2023 – 2026Coverage
Upcoming catalysts 3
Event history 57
Jun 2026
◆Trial InitiationCTM-GDTTrial
Multi-site first-in-human Phase I trial of CTM-GDT planned with Universiti Malaya
no-option cancer patientssource ↗
Jun 2026
●IND SubmissionCTM-GDTIND
IND submission to Malaysian authorities for CTM-GDT
no-option cancer patientssource ↗
Jan 28, 2026
▲Trial InitiationTrial
First-in-human clinical trial ongoing at National University Hospital, Singapore
cancerssource ↗
Jan 28, 2026
Jan 13, 2026
◆Enrollment UpdateCTM-N2DTrial
Six patients dosed in CTM-N2D Phase I trial
advanced colorectal cancer, lymphoma, multiple myeloma, lung cancer, ovarian cancer, hepatocellular carcinomasource ↗
Dec 8, 2025
▲Partnership / LicenseCorporate
Memorandum of Understanding with Universiti Malaya for CTM-GDT trial
Dec 8, 2025
◆Trial InitiationCTM-GDTTrial
First-in-human Phase I clinical trial of CTM-GDT planned with UMMC
no-option cancer patientssource ↗
Dec 8, 2025
◆Trial InitiationCTM-N2DTrial
Ongoing first-in-human Phase I trial of CTM-N2D in Singapore
advanced colorectal cancer, lymphoma, multiple myeloma, lung cancer, ovarian cancer, hepatocellular carcinomasource ↗
Nov 18, 2025
Nov 6, 2025
▲Partnership / LicenseCorporate
CytoMed secures non-dilutive investment for subsidiary LongevityBank from ICH Capital
Nov 6, 2025
▲Patent GrantedIP / Competition
Patent granted by China National Intellectual Property Administration for gamma delta T cell and CAR-T cell technology
cancersource ↗
Drug Pipeline Intelligence
F16
Pipeline Score $0M
Pipeline ValueValuation Signal
1
Drugs Scored—
rNPV / MCap Top 14%
Micro Cap (rank 784 of 911)
Percentile RankCytoMed Therapeutics Limited has significant pipeline risk (16/100), with 1 assets in development.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GDTC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GDTC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GDTCCytoMed Therapeutics Limited 1 Commonwealth Lane #08-22 Singapore 149544 PROXY STATEMENT AND NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To the shareholders of
CytoMed Therapeutics Limited has announced its Annual General Meeting (AGM) scheduled for May 22, 2026, at its office in Singapore. Shareholders are encouraged to vote either by internet or mail, whether or not they attend the meeting. The AGM will address various proposals, including the adoption of financial statements, re-elections of directors, and the appointment of public accounting firms. Shareholders can also participate via a webcast if they are unable to attend in person.
Read more →GDTCCytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
CytoMed Therapeutics has issued a statement refuting misleading claims about its clinical progress and operations. The company emphasizes its commitment to developing CAR γδ T cell therapies and confirms that its lead program is currently undergoing a first-in-human clinical trial. CytoMed aims to clarify its regulatory standing and operational integrity amidst public misinformation.
Read more →GDTCCytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital
CytoMed Therapeutics has updated shareholders on its progress and plans for 2026, including the development of new therapies and a Phase I clinical trial for gamma delta T cells. The company is also exploring innovative ways to enhance shareholder value and has received government support for its initiatives. Additionally, they are seeking feedback from shareholders on a new scheme related to their therapies.
Read more →GDTCCytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Tre
CytoMed Therapeutics Limited announced a collaboration with Universiti Malaya Medical Centre to conduct a first-in-human Phase I clinical trial for its allogeneic Gamma Delta T cells. This partnership aims to explore the safety and efficacy of its donor-derived immunotherapy for cancer patients in Malaysia. The initiative represents a step towards providing more affordable and accessible treatment options, particularly for those with limited alternatives. CytoMed's innovative technology may enhance cancer treatment landscapes in Southeast Asia, building on supportive findings from past studies.
Read more →GDTCCytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India Singapore, Singapore - (
CytoMed Therapeutics has finalized its acquisition of the TCB-002 technology from TC BioPharm Limited, aimed at enhancing its cancer treatment capabilities. The technology, which has received orphan drug designation from the FDA for Acute Myeloid Leukemia, will support CytoMed's development of affordable allogeneic gamma delta T cell immunotherapies. The company is in talks with potential partners to adapt the technology for use in China and India, following recent regulatory changes in China that favor the clinical use of cellular therapies. The financial impact of this acquisition is not expected to be immediate.
Read more →GDTCCytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy Singapore, Singapore - (
CytoMed Therapeutics has successfully secured a non-dilutive investment of up to $500,000 for its subsidiary, LongevityBank, from ICH Capital. The investment aims to enhance LongevityBank's focus on autologous therapies, leveraging personalized cellular banking services. Alongside this, CytoMed is repositioning its strategies toward the Chinese market, especially to introduce cost-effective cell therapy solutions. Notably, the company plans to offer free access to clinical trials for qualified shareholders, reflecting its commitment to innovative cancer care.
Read more →GDTCCytoMed Therapeutics' Chairman Increases Effective Holdings to 21.95% Singapore, Singapore - (
CytoMed Therapeutics Limited announced that its Executive Chairman, Peter Choo, has increased his holdings to 21.95% following recent share purchases. Choo expressed confidence in the company's proprietary technologies aimed at affordable cancer treatments amid rising investor interest in biotherapeutics, particularly in Asia. The company has highlighted opportunities due to the region's growing healthcare ecosystem and favorable regulatory environment. However, investors are cautioned to proceed carefully as updates on further purchases and potential risks are forthcoming.
Read more →GDTC▲ +16.6%on this news
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited's relevant assets Singapore, Singapore - (
CytoMed Therapeutics Limited has announced a cash bid for the potential acquisition of relevant assets from TC BioPharm Limited, which is currently under administration. This Proposed Acquisition aims to strengthen CytoMed's expertise in donor-derived cell therapies for cancer treatment, potentially speeding up its commercialization process. CytoMed's Chairman, Peter Choo, highlighted advancements in using gamma delta T cells and the company’s strategic focus on making therapies more accessible in Southeast Asia. The company is also funding the acquisition through its internal resources, with more details expected to follow.
Read more →GDTCCytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic T Cells in Acute Myeloid Leukemia Singapore, Singapo
CytoMed Therapeutics has published a preclinical study in collaboration with MD Anderson Cancer Center, highlighting the potential of their allogeneic T cell therapy in treating acute myeloid leukemia (AML). The findings support further clinical research into this therapy, suggesting a promising approach to treatment. The publication follows a previous research agreement established in May 2023, with plans to advance their T cell-based products into clinical trials in Southeast Asia. This collaboration aims to provide novel immunotherapy options for patients with limited alternatives.
Read more →GDTCCYTOMED THERAPEUTICS LIMITED AND SUBSIDIARIES UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS INDEX Page Unaudited Interim Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Loss fo
Cytomed Therapeutics Limited reported its unaudited interim condensed consolidated financial statements for the six months ending June 30 for the years 2024 and 2025. The company experienced significant financial strain, with a loss before income tax of S$2,245,828 in 2025, marking a deepening financial crisis. Comprehensive losses also rose sharply, totaling S$2,269,263 over the same period, alongside accumulated losses totaling S$17,091,895. These losses reflect both operating expenses that outpaced revenue generation and increased financial liabilities.
Read more →GDTCUpdate on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition Singapore, Singapore - (
CytoMed Therapeutics has announced its expansion into auto-immune disease therapies following the acquisition of a licensed cord blood bank in Malaysia. The company plans to leverage its resources to create new cord blood-derived therapeutics, particularly focusing on natural killer (NK) cells. This strategic move is expected to establish new revenue streams while also enhancing its overall clinical offerings. CytoMed's management has indicated a commitment to invest significantly in new equipment to support this initiative.
Read more →GDTCCytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program SINGAPORE
CytoMed Therapeutics Limited has announced an At-the-Market (ATM) offering program through which it can raise up to $4.3 million. This financing initiative is aimed at supporting general corporate purposes, including potential acquisitions and strategic investments. The Company has shown positive engagement with approximately 2,500 new customer sign-ups for its cord blood bank since its acquisition in August 2024, contributing to revenue growth in 2025. The timing and amount of sales will depend on market conditions and the Company’s capital needs.
Read more →GDTCUpdate On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies SI
CytoMed Therapeutics has announced the successful completion of dose level 1 of its Phase I ANGELICA Trial, which is investigating a new treatment for advanced solid tumors and hematological malignancies. The trial focuses on allogeneic CAR gamma delta T cells, specifically targeting NKG2DL, providing a novel approach to cancer therapy. Following the completion of the first dose level, the company is set to advance to dose level 2, marking a significant milestone in its clinical development efforts. This trial could offer new treatment avenues for patients with challenging cancers.
Read more →GDTC▲ +5.7%on this news
CytoMed Therapeutics Reports Full Year Ended
CytoMed Therapeutics reported its financial results for the year ended December 31, 2024, showing a significant reduction in net losses and sustained operational growth. The company is actively pursuing clinical developments, including its first CAR T trial involving gamma delta T cells, and plans to expand its technology platforms in the ASEAN region. A cord blood bank acquisition aims to support new therapeutic developments in autoimmune conditions and cancers. Nevertheless, they must remain vigilant amid global economic uncertainties while capitalizing on the positive momentum in their clinical programs.
Read more →GDTCCytoMed Therapeutics signs Business & Research Collaboration Agreement with India's SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in
CytoMed Therapeutics has entered into a Business & Research Collaboration Agreement with SunAct Cancer Institute to advance the use of allogeneic gamma delta T Cells for the treatment of solid cancers. The collaboration will facilitate an accelerated clinical trial in India, focusing on safety, efficacy, and optimal dosing. This partnership aims to provide accessible cancer therapies while contributing to global cancer treatment data. CytoMed would be responsible for the manufacturing of the T cells, while SunAct's expertise will aid in conducting the trials.
Read more →GDTC▲ +10%on this news
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haema
CytoMed Therapeutics has announced that the first patient has been dosed in its Phase I clinical trial, known as the ANGELICA Trial, evaluating allogeneic CAR-Gamma Delta T Cell therapy for advanced solid tumors and hematological malignancies. The trial aims to examine the safety and efficacy of this novel therapeutic approach, which leverages donor blood-derived cells. This milestone is significant for the company as it expands its clinical capabilities in the immunotherapy space. CytoMed, a spin-off from Singapore's A*STAR, focuses on innovative cell-based treatments for various cancers.
Read more →GDTC▲ +10%on this news
CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the N
CytoMed Therapeutics Limited has announced the initiation of its first-in-human Phase I ANGELICA clinical trial, which focuses on utilizing its patented donor allogeneic chimeric antigen receptor T cell therapy against various blood and solid tumors. Supported by co-funding from the National Medical Research Council (NMRC) of Singapore, the trial aims to recruit patients suffering from relapsed cancer. This innovative approach involves using gamma delta T cells, which can be modified from healthy donors, potentially allowing for more accessible cancer treatments. Additionally, CytoMed has recently acquired a cord blood bank to enhance its research and development capabilities.
Read more →GDTCCytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank SINGAPORE
CytoMed Therapeutics has acquired the cord blood banking license and assets from Cellsafe International through its subsidiary, IPSC Depository Sdn Bhd. This strategic move, which includes over 12,000 cord blood units and cryopreservation equipment, aims to bolster the company's focus on cord blood-derived biologics. The acquisition is expected to enhance CytoMed's capabilities in cell therapy, particularly in targeting regenerative medicine and combating various diseases. The company plans to develop this subsidiary further, with future plans for it to be spun off.
Read more →GDTC▲ +5.6%on this news· ran to +17% by day 1
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies SINGAPORE
CytoMed Therapeutics Limited has received board approval to launch a pilot program offering complimentary cell banking for shareholders holding at least 10,000 shares. The program aims to isolate and cryo-store peripheral blood mononuclear cells (PBMCs) to develop future cell-based therapies. Set to begin on June 1, 2024, it caters specifically to 200 qualified shareholders, providing them access to their own stored cells for potential medical use. Participants will benefit from waived storage fees for the first year, along with free scientific consultations on their stored PBMCs.
Read more →GDTCCytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair CytoMed diversi
CytoMed Therapeutics Limited has announced a research collaboration with Singapore Sengkang General Hospital to advance the use of injectable umbilical cord-derived mesenchymal stem cells (UC-MSCs) for cartilage repair. This therapy aims to treat cartilage injury and support a proposed Phase 1 clinical trial focusing on osteoarthritis of the knee. The collaboration marks a significant step in regenerative medicine and aims to establish proof-of-concept for this innovative therapeutic approach. CytoMed will provide UC-MSCs processed in its GMP laboratory, while SKH will contribute infrastructure and scientific data analysis.
Read more →GDTCMalaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology The Company now has exclusive rights to a Malaysia, US and China patent. Singapore, Singapore - (
CytoMed Therapeutics Limited has been granted a patent in Malaysia for its CAR-Gamma Delta T Cell technology aimed at treating various cancers. This patent adds to its existing intellectual property in the US and China, enhancing its position in the biopharmaceutical field. The patent covers the clinical-scale expansion and modification of T cells to better target tumors. CytoMed's chairman noted the significance of this grant as the company prepares for its first in-human clinical trial in Singapore.
Read more →GDTCCytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its...
CytoMed Therapeutics has signed a Heads of Agreement with CytoMed China and a Memorandum of Understanding with BioNex Solutions to advance research on allogeneic gamma delta T cell technology for cancer treatment. The collaboration aims to initiate an investigator-initiated trial in China, leveraging local expertise and resources. CytoMed's technology has recently received patent approval in China, indicating a positive regulatory environment for cell therapies.
Read more →GDTC▼ -8.6%on this news
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its...
CytoMed Therapeutics Limited reported its financial results for the first half of 2023, highlighting a net loss of S$1.16M and a successful IPO raising S$12.94M. The company has begun a Phase I clinical trial for its allogeneic CAR-γδ T cell therapy in Singapore. CytoMed is focused on advancing its proprietary technologies for cancer treatment.
Read more →GDTCCytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its...
CytoMed Therapeutics Limited (NASDAQ: GDTC) announced its participation in The Benchmark Company's 12th Annual Discovery One-on-One Investor Conference on December 7, 2023. The event will take place at the New York Athletic Club, where CytoMed will engage in one-on-one meetings with institutional and individual investors. This conference aims to foster connections between emerging companies and potential investors.
Read more →GDTC▲ +6.5%on this news
Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-based Technology Singapore, Singapore - (
CytoMed Therapeutics Limited announced that it has received a patent for its licensed induced pluripotent stem cell (iPSC)-based technology from the China National Intellectual Property Administration. This patent adds to the company's existing portfolio, which already includes patents in the US and Japan. The technology aims to create synthetic hybrid immune cells, known as NKT cells, that can recognize a diverse range of cancers, and is currently under preclinical development. Additionally, CytoMed plans to initiate a phase I clinical trial of its CAR-T cell technology in Singapore soon.
Read more →GDTC▲ +6.5%on this news
Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its...
CytoMed Therapeutics Limited announced the granting of a Chinese patent for its licensed iPSC-based technology, enhancing its patent portfolio which now includes patents in China, Japan, and the US. This technology focuses on developing allogeneic immunotherapies for cancer treatment, specifically utilizing γδ NKT cells. The company plans to initiate a Phase I clinical trial for its CAR-γδ T cell technology in Singapore soon.
Read more →GDTCCytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its...
CytoMed Therapeutics has signed a Memorandum of Understanding with Hangzhou CNK Therapeutics to enhance its allogeneic CAR γδ T cell therapies. This collaboration will utilize CNK's PiggyBac technology for permanent CAR gene integration, potentially increasing treatment efficacy. The MOU is valid for one year and may lead to joint clinical trials in China.
Read more →GDTCChinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology The Company now has exclusive rights to a US and Chinese patent. Singapore, Singapore - (
CytoMed Therapeutics Limited has been granted exclusive rights to a Chinese patent for its allogeneic CAR-Gamma Delta T Cell technology, licensed from A*STAR. This development comes as the company prepares to initiate its first in-human trial for CAR-T cells in Singapore later this year. The patent covers methods for expanding and modifying T cells to enhance their cancer-fighting capabilities. Additionally, CytoMed aims to establish partnerships in the Chinese market to leverage its new intellectual property.
Read more →GDTC▲ +6.2%on this news· ran to +84% by day 3
A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US Singapore
CytoMed Therapeutics, a spinoff from A*STAR, announced that it has secured a US patent for its licensed CAR-gamma delta T cell technology, enhancing its immunotherapy capabilities for cancer treatment. The patent allows CytoMed to develop a method for expanding T cells from donor blood and modifying them to target various cancers. The company is set to initiate its first-in-human clinical trial in Singapore soon, receiving approval from local health authorities. This development signifies a substantial step for CytoMed, positioning it for further advancements in the cancer treatment landscape.
Read more →GDTCCytomed Therapeutics Limited Announces Pricing of Initial Public Offering Singapore
CytoMed Therapeutics Limited announced the pricing of its initial public offering, selling 2,412,369 ordinary shares at $4.00 each, aiming for gross proceeds of approximately $9.65 million. The shares are set to trade on the Nasdaq Capital Market under the ticker GDTC on April 14, 2023. Proceeds from the offering will primarily support the clinical development of its product candidates and further R&D activities. The offering is subject to customary closing conditions and includes an option for underwriters to purchase additional shares.
Read more →Competitive Position
How GDTC ranks across every disease it competes inCompetitive Position is a premium feature
See how GDTC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial